TP53 and non-small cell lung carcinoma: This suggests that nultin-3a has a significant potential for treating KRAS MT/p53 WT NSCLC cells and overcoming the resistance developed by cancer cells, which currently has limited treatment options, even though the underlying mechanism needs to be further investigated.